Categories
News

Human Insulin Market 2020 Global Share, Future Growth, Demand and Forecasts to 2026

Fillings & Toppings Market
Fillings & Toppings Market

The global “human insulin market” size is anticipated to reach USD 27.71 billion by 2026. International Diabetes Federation (IDF) reported that around 425 million people across the world suffer from diabetes. This shows that the rising prevalence of diabetes is propelling growth in the market. Fortune Business Insights in a new report, titled “Human Insulin Market Size, Share & Industry Analysis, By Type (Analogue Insulin (Long-Acting, Fast Acting, Premix), Traditional Human Insulin (Long-Acting, Short-Acting, Fast Acting, Premix)), By Diabetes Type (Type 1, Type 2), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), and Regional Forecast, 2019-2026” predicts the market to exhibit a CAGR of 3.4% during the forecast period. In 2018, the market value stood at USD 21.26 billion in 2018. The adoption of delivery devices primarily for insulin administration is increasing, thus driving the market. The report provides market analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product & service launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/human-insulin-market-100395

Eli Lilly & Company to Launch Analogue Humalog Insulin in the U.S.

Among products, analogue insulin covered the maximum part in the human insulin market share in 2018. Analogue insulin helps to control blood sugar levels in people suffering from type 1 and type 2 diabetes. Driven by this, the adoption of analogue insulin is increasing, which increases the human insulin market size. This, coupled with the recent launch of generic insulin, is expected to contribute to the growth of the market. For instance, Eli Lilly and Company announced the launch of a generic version of analogue Humalog insulin called Insulin Lispro in April 2019. Owing to the cheaper rates of Humalog, this insulin is more accessible to diabetic patients in the country. This segment is expected to drive the human insulin market in the foreseeable future.

Key Companies and Manufacturers Covered:

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Boston Scientific Corporation
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Biocon
  • Tonghua Dongbao Pharmaceutical
  • Julphar
  • Wockhard
  • Other prominent players

Novo Nordisk to Expand its Insulin Manufacturing Plant in India

The prevalence of diabetes is increasing across the world, one of the primary human insulin market trends. In a 2017 report published by the Centers for Diseases Control and Prevention (CDC), it was found that around 30.3 million people in the U.S. suffered from diabetes. Furthermore, it was stated that among the above numbers, around 23.1 million were diagnosed, while the rest were not diagnosed. The increasing adoption of a sedentary lifestyle is the primary reason behind the prevalence of diabetes. This, as a result, will fuel demand for insulin pens and insulin injections among masses. Consequently, Biocon plans to develop an oral insulin tablet called Tregopil for people suffering from Type 1 and Type 2 diabetes. This tablet aims to improve the post-prandial blood sugar control and has minimum side-effects. As per the report, companies such as Eli Lilly and Company, Sanofi, and Novo Nordisk A/S hold the maximum share in the global market.

View For More [email protected] https://www.globenewswire.com/news-release/2020/01/06/1966400/0/en/Human-Insulin-Market-to-Reach-USD-27-71-Billion-by-2026-Technological-Advancements-in-Insulin-Pens-to-Spur-Growth-Fortune-Business-Insights.html

Human Insulin Market Segmentation:

By Type

  • Analogue Insulin
    • Long-acting
    • Fast-acting
    • Premix
  • Traditional Human Insulin
    • Long-acting
    • Short-acting
    • Fast-acting
    • Premix

By Diabetes Type

  • Diabetes Type 1
  • Diabetes Type 2

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Reasons to Purchase this Report:

  • Detailed business profiles including product offerings, recent developments, key financial information, and strategies employed by main market players.
  • Analysis of various regions and countries that includes the demand and supply based actions, which consequently have a major influence on the market’s expansion.
  • Market dynamics and opportunities for growth for players in the near future.
  • Competitive landscape describing the market revenue shares of key players.
  • Market segmentation analysis that deals with quantitative and qualitative research, discussing the influence of policy-based and economical aspects.

Our proven methodologies and systematic analysis help in making confident business and strategic decisions.

A market study that conducts at Fortune Business Insights can save significant cost and time, and can help prevent making costly mistakes.

Related Reports:

Surgical Stapling Devices Market 2020 Industry Size, Growth Analysis, Regional Overview and Forecast till 2026

Veterinary Diagnostics Market Global Industry Share 2020, Development, Regional Demand, Trends and Industry Forecast Report 2026

Aesthetic Lasers Market 2020 Future Growth, Leading Players Updates, Industry Demand and Forecast to 2026

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email:[email protected]

Linkedin | Twitter | BLogs

Categories
Press Release

Human Insulin Market 2019 Trends Plans, Business Opportunities, Industry Share, Global Size Analysis

The growing prevalence of diabetes across the world is prophesied to expand the global human insulin market. The above information was provided by Fortune Business Insights in a report, titled “Human Insulin Market Size, Share and Global Trend by Drug Type (Biologics, Biosimilar), By Delivery Devices (Vials & Syringes, Insulin Pens, Insulin Pumps), By Type of Patients (Type 1 diabetes, Type 2 diabetes), By Mode of Action (Long-Acting, Rapid-Acting, Short-Acting, Intermediate-Acting, Premix Insulin), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography Forecast till 2026.” These numbers are primarily increasing on account of growing obesity rates. The International Diabetes Foundation (IDF) estimates the prevalence of diabetes to grow in the coming years. The number of diabetic patients registered in 2017 were 425 Million and is projected to reach 629 Million by 2045.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/human-insulin-market-100395

Market Advances with Rapid Improvements in Insulin Delivery in North America

Among regions, North America is anticipated to dominate the global human insulin market during the forecast period. The growth is majorly witnessed on account of the rising prevalence of diabetes and its related disorders. Furthermore, the demand for human infusion insulin devices is increasing owing to their availability and technological improvements.  On the other hand, the market in Asia Pacific is likely to witness high growth between 2018 and 2026. The rising research and development (R&D) investments and presence of well-known manufacturing companies in this region are creating ample growth opportunities for the market. These companies are likely to boost the human insulin market in the upcoming years.

Introduction of Insulin Pens Intended to Offer Ease of Use to Patients

As per research studies, the number of type 2 diabetes patients is increasing owing to its onset at a younger age. Rapid lifestyle changes and unhealthy eating habits are predominantly leading to type 2 diabetes. These patients are treated with different types of insulin as per the requirements. Some of them include rapid-acting insulin, long-acting insulin, short-acting insulin, and premix insulin. The demand for these insulins are expected to increase in the coming years, which in turn, will increase the human insulin production. The introduction of insulin delivery devices such as safety insulin pens and pumps are likely to propel growth of the market. With the emergence of technology, novel insulin pens with added features are likely to gain traction in the coming years.

The World Health Organization (WHO) has recently developed an action plan to prevent and control non-communicable diseases or NCDs. The plan was implemented in South-East Asia and offered a roadmap for different programmes and policies at local and international level. This is further expected to transform the human insulin structure, thus driving the human insulin market.

Sanofi’s Launch of Admelog Intends to Improve Blood Sugar Levels in Patients

Some of the leading players operating in the global human insulin market include Novo Nordisk, Sanofi A/S, Eli Lilly & Company, Astra Zeneca plc, GlaxoSmithKline plc, Tonghua Dongbao Pharmaceutical Co., Biocon, Julphar, and Wockhardt. Sebveral compaies are planning to focus on collaborations and partnerships to gain market share. For instance, Ypsomed AG partnered with with Koninklijke Philips N.V. in October 2018. The aim of this collaboration was to conjointly develop and deploy novel self-medication monitoring services. In November 2018, Biocon and Mylan announced the launch of a new biosimilar called Semglee. The drug is indicated to treat patients suffering from diabetes mellitus in adults and children. Companies are also focussing to launch new products to stay industry focussed. For instance, Sanofi launched an insulin lispro product called Admelog in April 2018. This product is intended to control insulin levels in children and adults.

More Trending Topics From Fortune Business [email protected]

Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market to Reach US$ 1959.8 Mn by 2026

Global Veterinary Drugs Market to Worth US$ 27,570 Mn Gaining Impetus from Government Support

Categories
Press Release

Human Insulin Market Industry Growth Analysis and Leading Players by Forecast to 2026

The growing prevalence of diabetes across the world is prophesied to expand the global human insulin market. The above information was provided by Fortune Business Insights in a report, titled “Human Insulin Market Size, Share and Global Trend by Drug Type (Biologics, Biosimilar), By Delivery Devices (Vials & Syringes, Insulin Pens, Insulin Pumps), By Type of Patients (Type 1 diabetes, Type 2 diabetes), By Mode of Action (Long-Acting, Rapid-Acting, Short-Acting, Intermediate-Acting, Premix Insulin), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography Forecast till 2026.” These numbers are primarily increasing on account of growing obesity rates. The International Diabetes Foundation (IDF) estimates the prevalence of diabetes to grow in the coming years. The number of diabetic patients registered in 2017 were 425 Million and is projected to reach 629 Million by 2045.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/human-insulin-market-100395

Market Sees Stronger Sales of Biosimilars Than Other Drugs

As per drug type, biosimilars are projected to grow at a considerable rate throughout the forecast years. The cost-effectiveness of these drugs is expected to fuel their demand in the coming years. Furthermore, the U.S. Food and Drug Administration revealed that biosimilars are safe and effective for the treatment of diabetes.

Market Advances with Rapid Improvements in Insulin Delivery in North America

Among regions, North America is anticipated to dominate the global human insulin market during the forecast period. The growth is majorly witnessed on account of the rising prevalence of diabetes and its related disorders. Furthermore, the demand for human infusion insulin devices is increasing owing to their availability and technological improvements.  On the other hand, the market in Asia Pacific is likely to witness high growth between 2018 and 2026. The rising research and development (R&D) investments and presence of well-known manufacturing companies in this region are creating ample growth opportunities for the market. These companies are likely to boost the human insulin market in the upcoming years.

Request Sample [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/human-insulin-market-100395

Sanofi’s Launch of Admelog Intends to Improve Blood Sugar Levels in Patients

Some of the leading players operating in the global human insulin market include Novo Nordisk, Sanofi A/S, Eli Lilly & Company, Astra Zeneca plc, GlaxoSmithKline plc, Tonghua Dongbao Pharmaceutical Co., Biocon, Julphar, and Wockhardt. Sebveral compaies are planning to focus on collaborations and partnerships to gain market share. For instance, Ypsomed AG partnered with with Koninklijke Philips N.V. in October 2018. The aim of this collaboration was to conjointly develop and deploy novel self-medication monitoring services. In November 2018, Biocon and Mylan announced the launch of a new biosimilar called Semglee. The drug is indicated to treat patients suffering from diabetes mellitus in adults and children. Companies are also focussing to launch new products to stay industry focussed. For instance, Sanofi launched an insulin lispro product called Admelog in April 2018. This product is intended to control insulin levels in children and adults.

Introduction of Insulin Pens Intended to Offer Ease of Use to Patients

As per research studies, the number of type 2 diabetes patients is increasing owing to its onset at a younger age. Rapid lifestyle changes and unhealthy eating habits are predominantly leading to type 2 diabetes. These patients are treated with different types of insulin as per the requirements. Some of them include rapid-acting insulin, long-acting insulin, short-acting insulin, and premix insulin. The demand for these insulins are expected to increase in the coming years, which in turn, will increase the human insulin production. The introduction of insulin delivery devices such as safety insulin pens and pumps are likely to propel growth of the market. With the emergence of technology, novel insulin pens with added features are likely to gain traction in the coming years.

More Trending Topics From Fortune Business [email protected]

Crop Protection Chemicals Market to Reach US$ 68.82 Bn by 2025 says Fortune Business Insights

Veterinary Drugs Market to Reach US$ 27,570 Mn Company Overview and Forecast by 2025

Dialyzers Market Research 2019, Key Findings, Business Opportunity and Forecast to 2026

Categories
Press Release

Human Insulin Market 2019 Global Industry Growth Analysis and Leading Players Updates

The growing prevalence of diabetes across the world is prophesied to expand the global human insulin market. The above information was provided by Fortune Business Insights in a report, titled “Human Insulin Market Size, Share and Global Trend by Drug Type (Biologics, Biosimilar), By Delivery Devices (Vials & Syringes, Insulin Pens, Insulin Pumps), By Type of Patients (Type 1 diabetes, Type 2 diabetes), By Mode of Action (Long-Acting, Rapid-Acting, Short-Acting, Intermediate-Acting, Premix Insulin), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography Forecast till 2026.” These numbers are primarily increasing on account of growing obesity rates. The International Diabetes Foundation (IDF) estimates the prevalence of diabetes to grow in the coming years. The number of diabetic patients registered in 2017 were 425 Million and is projected to reach 629 Million by 2045.

 Request Sample [email protected]  https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/human-insulin-market-100395 

Market Sees Stronger Sales of Biosimilars Than Other Drugs

As per drug type, biosimilars are projected to grow at a considerable rate throughout the forecast years. The cost-effectiveness of these drugs is expected to fuel their demand in the coming years. Furthermore, the U.S. Food and Drug Administration revealed that biosimilars are safe and effective for the treatment of diabetes.

Market Advances with Rapid Improvements in Insulin Delivery in North America

Among regions, North America is anticipated to dominate the global human insulin market during the forecast period. The growth is majorly witnessed on account of the rising prevalence of diabetes and its related disorders. Furthermore, the demand for human infusion insulin devices is increasing owing to their availability and technological improvements.  On the other hand, the market in Asia Pacific is likely to witness high growth between 2018 and 2026. The rising research and development (R&D) investments and presence of well-known manufacturing companies in this region are creating ample growth opportunities for the market. These companies are likely to boost the human insulin market in the upcoming years.

Speak to [email protected] https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/human-insulin-market-100395 

Introduction of Insulin Pens Intended to Offer Ease of Use to Patients

As per research studies, the number of type 2 diabetes patients is increasing owing to its onset at a younger age. Rapid lifestyle changes and unhealthy eating habits are predominantly leading to type 2 diabetes. These patients are treated with different types of insulin as per the requirements. Some of them include rapid-acting insulin, long-acting insulin, short-acting insulin, and premix insulin. The demand for these insulins are expected to increase in the coming years, which in turn, will increase the human insulin production. The introduction of insulin delivery devices such as safety insulin pens and pumps are likely to propel growth of the market. With the emergence of technology, novel insulin pens with added features are likely to gain traction in the coming years.

The World Health Organization (WHO) has recently developed an action plan to prevent and control non-communicable diseases or NCDs. The plan was implemented in South-East Asia and offered a roadmap for different programmes and policies at local and international level. This is further expected to transform the human insulin structure, thus driving the human insulin market.

Contrary to this, less availability of patient-friendly insulin devices and mounting costs of branded products may hamper the growth of the market.

Sanofi’s Launch of Admelog Intends to Improve Blood Sugar Levels in Patients

Some of the leading players operating in the global human insulin market include Novo Nordisk, Sanofi A/S, Eli Lilly & Company, Astra Zeneca plc, GlaxoSmithKline plc, Tonghua Dongbao Pharmaceutical Co., Biocon, Julphar, and Wockhardt. Sebveral compaies are planning to focus on collaborations and partnerships to gain market share. For instance, Ypsomed AG partnered with with Koninklijke Philips N.V. in October 2018. The aim of this collaboration was to conjointly develop and deploy novel self-medication monitoring services. In November 2018, Biocon and Mylan announced the launch of a new biosimilar called Semglee. The drug is indicated to treat patients suffering from diabetes mellitus in adults and children. Companies are also focussing to launch new products to stay industry focussed. For instance, Sanofi launched an insulin lispro product called Admelog in April 2018. This product is intended to control insulin levels in children and adults.

More Trending Topics From Fortune Business [email protected]

Women’s Health Technology Market 2019: Global Industry Overview By Size, Opportunities and Industry Segments Poised for Rapid Growth by 2026

Home Rehabilitation Products Market 2019 Industry Share, Size, Global Research, Top Leading Players, Region by Forecast

Intrathecal Pumps Market 2019 Trends, Statistics, Size, by Key Players | Industry Forecast by Categories